Olvi-Vec (olvimulogene nanivacirepvec)

About Genelux

Genelux is pioneering a novel class of oncolytic virotherapies based on its proprietary, genetically modified vaccinia virus platform. The company's lead asset, Olvi-Vec, is in Phase 2/3 development for platinum-resistant/refractory ovarian cancer, with data suggesting potential for improved survival and immune activation. Genelux's strategy centers on demonstrating the efficacy of its platform as a monotherapy and in combination with other immunotherapies to address significant unmet needs in oncology.

Therapeutic Areas